The aim of this work is to review the preclinical and, when
available, clinical evidence of second-generation sulfonylureas
and new diarylsulfonylurea (DSU) effects on tumor growth in order
to give an updated picture of current knowledge that might
contribute to progress in the area of diabetes and cancer.